BMT CTN Research Samples Collections

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) supports investigators engaged in retrospective immunogenetic and immunobiologic studies in hematopoietic cell transplantation by making available numerous research sample and clinical data collections from our BMT CTN clinical trials.  The following protocol-specific links will provide investigators with the following resources:

  • Clinical protocols to review primary and secondary endpoints and other relevant clinical data collected in each trial.
  • Information regarding prospective research sample collection schedules, sample processing, and sample type storage.
  • Protocol-specific research sample collection summaries to facilitate initial assessments of available research samples for future ancillary study planning.
  • Overview of BMT CTN procedures for reviewing and approving ancillary study proposals and current proposal submission form.
BMT CTN 0101 A Randomized Double-blind Trial of Fluconazole vs. Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Recipients
BMT CTN 0102 A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy versus Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients with Multiple Myeloma
BMT CTN 0201 A Phase III Randomized Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell with Marrow Transplantation from HLA Compatible Unrelated Donors
BMT CTN 0302 Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (Ontak), and Pentostatin in Combination with Corticosteroids
BMT CTN 0401 Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin’s Lymphoma
BMT CTN 0402 A Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as GVHD Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation
BMT CTN 0701 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin’s Lymphoma Beyond First Complete Response
BMT CTN 0702 A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
BMT CTN 07LT Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702
BMT CTN 0801 A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease
BMT CTN 0802 A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids with Mycophenolate Mofetil vs. Corticosteroids with Placebo as Initial Systemic Treatment of Acute GVHD
BMT CTN 0803 High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients
BMT CTN 0901 A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
BMT CTN 0903 Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodyplastic Syndromes in HIV-infected Patients
BMT CTN 1101 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies
BMT CTN 1102 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome
BMT CTN 1202 Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT
BMT CTN 1203 A Multi-Center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls
BMT CTN 1204 Reduced-Intensity Conditioning for Children and Adults with Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI)
BMT CTN 1301 A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease
BMT CTN 1302 Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
BMT CTN 1401 Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma Fusions
BMT CTN 1501 A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease

BMT CTN Contacts for Questions and Assistance

◊ BMT CTN Research Sample Collection Inquiries:

Alan Howard (ahoward@nmdp.org) or Stephen Spellman (sspellma@nmdp.org)

Ancillary Study Proposal Submissions and Approval Process

Review Procedure Overview: Chapter 11, BMT CTN Administrative MOP

Ancillary Study Review & Approval Process Summary (1 page): Review and Approval Summary

Ancillary Study Proposal Form:  Please download and complete form and submit by email to Alan Howard (ahoward@nmdp.org) or Stephen Spellman (sspellma@nmdp.org).